Form 4 for EW Edwards Lifesciences
Accepted 2022-05-10 00:00:00 ET · period of report 2022-05-08 · accession 0001225208-22-006818 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-10 | 2022-05-10 | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | G - Gift | $0.00 | -12.5K | 170.5K | -7% | $0 |
| DM | 2022-05-10 | 2022-05-10 | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | S - Sale+OE | $94.82 | -32.5K | 195.0K | -14% | -$3.09M |
| DM | 2022-05-10 | 2022-05-08+ | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | M - OptEx | $9.62 | +101.9K | 157.4K | +184% | +$980.3K |
| DI | 2022-05-10 | 2022-05-10 | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | G - Gift | $0.00 | +12.5K | 3.41M | +0.4% | $0 |
| DM | 2022-05-10 | 2022-05-08+ | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | M - OptEx | $0.00 | -101.9K | 48.7K | -68% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-10 | G | D | 12,500 | $0.00 | 170,450.82 | D | — | — | |
| 2 | Common | Common Stock | 2022-05-10 | S | D | 12,028 | $95.39 | 182,950.82 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $94.900 to $95.900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2022-05-10 | S | D | 2,724 | $96.12 | 199,678.82 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $95.905 to $96.470. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2022-05-10 | M | A | 45,050 | $21.76 | 202,402.82 | D | — | — | |
| 5 | Common | Common Stock | 2022-05-08 | M | A | 56,831 | $0.00 | 157,352.82 | D By Living Trust | — | — | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |
| 6 | Common | Common Stock | 2022-05-10 | S | D | 13,098 | $94.54 | 157,352.82 | D | — | — | (F6) This transaction was executed in multiple trades at prices ranging from $93.890 to $94.890. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Common | Common Stock | 2022-05-10 | G | A | 12,500 | $0.00 | 3,406,517 | I | — | — | |
| 8 | Common | Common Stock | 2022-05-10 | S | D | 4,700 | $93.41 | 194,978.82 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $92.880 to $93.880. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 9 | Derivative | Employee Stock Option (Right to Acquire) | 2022-05-10 | M | D | 45,050 | $0.00 | 0 | D | $21.76 · 2015-06-14 to 2022-05-13 | 45,050 Common Stock | |
| 10 | Derivative | Performance Rights | 2022-05-08 | M | D | 56,831 | $0.00 | 48,712 | D | — · 2022-05-08 to 2026-05-07 | 56,831 Common Stock | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |